All contributors
Onconephrology contributor
Kastritis, Efstathios
Primarily Myeloma cast nephropathy#11 of 46 recognizedHonor roll
63
Clinical papers
7,914
Citations (iCite)
15 / 14
First / senior author
2007–2026
Active years
Output over time
Clinical corpus papers per year — peak 7 in 2016, 2020, 2026.
- 2007: 2 papers
- 2008: 1 paper
- 2009: 4 papers
- 2010: 2 papers
- 2012: 3 papers
- 2013: 3 papers
- 2014: 3 papers
- 2015: 2 papers
- 2016: 7 papers
- 2017: 1 paper
- 2018: 1 paper
- 2019: 2 papers
- 2020: 7 papers
- 2021: 4 papers
- 2022: 1 paper
- 2023: 4 papers
- 2024: 4 papers
- 2025: 5 papers
- 2026: 7 papers
20072026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
Myeloma cast nephropathy45
MGRS & paraprotein kidney disease35
Cellular therapy renal effects2
Anticancer drug nephrotoxicity1
Frequent co-authors
Other recognized contributors who most often share corpus papers with Kastritis (shared-paper count).
Agents they study
Catalog agents whose clinical kidney literature lists Kastritis among the leading contributors (clinical-paper count on that agent).
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,541-article corpus (regenerated 2026-10-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.